Has Ryan Byrne received payments from drug or device companies?

Yes. Drug and device makers reported $1,754 in general payments to Ryan Byrne across 86 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ryan Byrne did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ryan Byrne come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ryan Byrne

Child & Adolescent Psychiatry · North Charleston, SCNPI 1063619773

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 10.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $882, 2.8 times the $315 reported in 2022.

$1,754in general payments, 2019–2025

Across 86 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$191
Otsuka America Pharmaceutical, Inc.$187
Almatica Pharma LLC$143
Takeda Pharmaceuticals U.S.A., Inc.$126
Alkermes, Inc.$115
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$113
plus $880 from 14 others

What the payments were for

Food & beverage$1,754100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	9	$191
Otsuka America Pharmaceutical, Inc.	10	$187
Almatica Pharma LLC	7	$143
Takeda Pharmaceuticals U.S.A., Inc.	6	$126
Alkermes, Inc.	6	$115
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	5	$113
Teva Pharmaceuticals USA, Inc.	7	$109
AbbVie	5	$97
Axsome Therapeutics, Inc.	3	$95
Neurocrine Biosciences, Inc.	4	$91
Collegium Pharmaceutical, Inc.	5	$88
Sunovion Pharmaceuticals Inc.	3	$73
E.r. Squibb & Sons, L.L.C.	3	$73
Corium, LLC	2	$61
Tris Pharma Inc	3	$49
Noven Therapeutics, LLC	2	$44
Supernus Pharmaceuticals, Inc.	2	$37
Neos Therapeutics, LP	2	$31
Idorsia Pharmaceuticals US Inc	1	$20
Vanda Pharmaceuticals Inc.	1	$13

How this compares

$1,754 in reported general payments places this provider in the 75th percentile of 71 child & adolescent psychiatry providers in South Carolina.

See all child & adolescent psychiatry providers in South Carolina →

Other child & adolescent psychiatry in North Charleston

Don DuboseColumbia$290K
Mary Theresa LaddCharleston$54K
Merrie CherryLexington$39K
Victor EvansLexington$26K
David SherbondyGreenville$19K
Eman SharawyGreenwood$9K
Elena DlugachGreenville$8K
Elizabeth JeffordsColumbia$5K
Vikram ShuklaClover$3K
Stephanie PriceCharleston$3K

See the full list for South Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →